

**NEULAND LABORATORIES LIMITED**

Sanali Info Park, 'A' Block, Ground Floor, 8-2-120/113, Road No. 2, Banjara Hills, Hyderabad - 500034

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2016**

(Amount in lakhs of ₹ unless otherwise stated)

Sl. No.	Particulars	Quarter Ended 30.09.2016 (Unaudited)	Quarter Ended 30.06.2016 (Unaudited)	Quarter Ended 30.09.2015 (Unaudited)	Half Year Ended 30.09.2016 (Unaudited)	Half Year Ended 30.09.2015 (Unaudited)	Year Ended 31.03.2016 (Audited)
1	<b>Income from operations</b>						
	(a) Net Sales / Income from Operations (net of excise duty)	14,442.89	14,558.44	12,404.40	29,001.33	24,316.88	48,576.71
	(b) Other Operating Income	515.98	418.16	413.89	934.14	873.39	2,420.30
	<b>Total Income from Operations (Net)</b>	<b>14,958.87</b>	<b>14,976.60</b>	<b>12,818.29</b>	<b>29,935.47</b>	<b>25,190.27</b>	<b>50,997.01</b>
2	<b>Expenses</b>						
	(a) Cost of Materials consumed	6,871.67	6,970.72	6,697.14	13,842.39	13,397.53	25,956.67
	(b) Changes in inventories of finished goods and work-in-progress	633.99	79.14	108.75	713.13	(266.60)	(611.18)
	(c) Employee benefits expense	1,559.22	1,666.16	1,454.95	3,225.38	2,982.59	5,989.23
	(d) Depreciation and amortisation expense	454.42	436.07	389.59	890.49	769.79	1,574.26
	(e) Manufacturing expenses	1,584.83	1,462.10	1,177.99	3,046.93	2,403.69	5,284.20
	(f) Sales promotion expenses including sales commission	714.32	1,512.20	262.70	2,226.52	413.87	2,039.90
	(g) Other expenses	1,073.49	830.05	1,164.85	1,903.54	2,196.69	4,351.22
	<b>Total expenses</b>	<b>12,891.94</b>	<b>12,956.44</b>	<b>11,255.97</b>	<b>25,848.38</b>	<b>21,897.56</b>	<b>44,584.30</b>
3	<b>Profit from operations before other income, finance costs and exceptional items (1-2)</b>	<b>2,066.93</b>	<b>2,020.16</b>	<b>1,562.32</b>	<b>4,087.09</b>	<b>3,292.71</b>	<b>6,412.71</b>
4	Other Income	(5.54)	48.70	(2.29)	43.16	50.57	161.91
5	<b>Profit from ordinary activities before finance costs and exceptional items (3+4)</b>	<b>2,061.39</b>	<b>2,068.86</b>	<b>1,560.03</b>	<b>4,130.25</b>	<b>3,343.28</b>	<b>6,574.62</b>
6	Finance Costs	522.42	609.68	627.79	1,132.10	1,281.89	2,446.60
7	<b>Profit from ordinary activities after finance costs but before exceptional items (5-6)</b>	<b>1,538.97</b>	<b>1,459.18</b>	<b>932.24</b>	<b>2,998.15</b>	<b>2,061.39</b>	<b>4,128.02</b>
8	Exceptional Items	-	-	-	-	-	-
9	<b>Profit from ordinary activities before tax (7-8)</b>	<b>1,538.97</b>	<b>1,459.18</b>	<b>932.24</b>	<b>2,998.15</b>	<b>2,061.39</b>	<b>4,128.02</b>
10	Tax expense	500.10	488.05	311.83	988.15	710.92	1,486.54
11	<b>Net profit from ordinary activities after tax (9-10)</b>	<b>1,038.87</b>	<b>971.13</b>	<b>620.41</b>	<b>2,010.00</b>	<b>1,350.47</b>	<b>2,641.48</b>
12	Extraordinary items	-	-	-	-	-	-
13	<b>Net profit for the period (11-12)</b>	<b>1,038.87</b>	<b>971.13</b>	<b>620.41</b>	<b>2,010.00</b>	<b>1,350.47</b>	<b>2,641.48</b>
14	Paid-up Equity Share Capital (Face value of ₹10 per share)	895.39	895.39	895.39	895.39	895.39	895.39
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	-	-	17,437.92
16.i	Earnings per share (before extraordinary items) (of ₹10 each) (In absolute ₹)						
	(a) Basic (not annualized)	11.69	10.93	6.98	22.62	15.20	29.73
	(b) Diluted (not annualized)	11.69	10.93	6.98	22.62	15.20	29.73
16.ii	Earnings per share (after extraordinary items) (of ₹10 each) (In absolute ₹)						
	(a) Basic (not annualized)	11.69	10.93	6.98	22.62	15.20	29.73
	(b) Diluted (not annualized)	11.69	10.93	6.98	22.62	15.20	29.73
	See accompanying notes to the financial results						



**NOTES:**

- 1 The above unaudited financial results have been reviewed by the Audit Committee at their meeting held on November 3, 2016, and approved and taken on record at the Board of Directors meeting held on November 4, 2016.
- 2 EPS for quarters are not annualized.
- 3 The Company's operations are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Accounting Standard - AS 17 "Segment Reporting".
- 4 The above unaudited financial results have been reviewed by the statutory auditors of the Company pursuant to regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
- 5 The board has accorded its approval for the Scheme of Amalgamation and Arrangement amongst the Company, Neuland Health Sciences Private Limited ("NHSPL") and Neuland Pharma Research Private Limited ("NPRPL") and their respective shareholders and creditors. As a part of the proposed transaction, both NHSPL and NPRPL will be amalgamating into the Company and consequently, new equity shares of the Company would be issued to the shareholders of NHSPL and NPRPL.
- 6 The Company has entered into a Joint Development Agreement (JDA) with Phoenix Embassy techno Zone Private Limited for development of the land owned by the Company at Nanakramguda, Hyderabad. In terms of the said JDA, the Company would be entitled to receive approximately 23% share of the saleable area of the proposed project, which would be duly determined on the basis of an approval of the building plans by the authorities concerned.
- 7 The statement of assets and liabilities is as follows:

(Amount in lakhs of ₹)

SI No	Particulars	As on 30.09.2016 (Unaudited)	As on 31.03.2016 (Audited)
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
1	Shareholders' Funds		
	(a) Share Capital	895.39	895.39
	(b) Reserves and Surplus	19,531.81	17,521.81
		20,427.20	18,417.20
2	Share Application Money Pending Allotment	-	-
3	Non-current Liabilities		
	(a) Long-term Borrowings	4,769.43	4,540.00
	(b) Deferred Tax Liability (Net)	1,421.10	1,422.82
	(c) Other Long-term Liabilities	253.00	253.00
	(d) Long-term Provisions	714.44	684.92
		7,157.97	6,900.74
4	Current Liabilities		
	(a) Short-term Borrowings	11,938.90	12,362.90
	(b) Trade Payables	10,127.39	8,332.28
	(c) Other Current Liabilities	5,511.26	5,774.29
	(d) Short-term Provisions	510.83	546.72
		28,088.38	27,016.19
	<b>TOTAL</b>	<b>55,673.55</b>	<b>52,334.13</b>
<b>B</b>	<b>ASSETS</b>		
1	Non-current Assets		
	(a) Fixed Assets	18,903.36	17,925.09
	(b) Non-current Investments	754.58	754.58
	(c) Long-term Loans and Advances	2,309.94	2,320.67
		21,967.88	21,000.34
2	Current Assets		
	(a) Inventories	12,081.80	12,666.29
	(b) Trade Receivables	15,528.10	11,910.83
	(c) Cash and Bank Balances	1,355.63	904.02
	(d) Short-term Loans and Advances	3,692.87	4,959.00
	(e) Other Current Assets	1,047.27	893.65
		33,705.67	31,333.79
	<b>TOTAL</b>	<b>55,673.55</b>	<b>52,334.13</b>

- 8 Previous period figures have been re-grouped/reclassified wherever necessary, to confirm to the current period's classification.



By Order of the Board  
For Neuland Laboratories Limited



Dr. D.R. Rao  
Chairman & Managing Director  
(DIN 00107737)

Place: Hyderabad  
Date: November 4, 2016